Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) Equity Average (2020 - 2025)

Foghorn Therapeutics has reported Equity Average over the past 6 years, most recently at -$99.1 million for Q4 2025.

  • Quarterly results put Equity Average at -$99.1 million for Q4 2025, down 168.45% from a year ago — trailing twelve months through Dec 2025 was -$99.1 million (down 168.45% YoY), and the annual figure for FY2025 was -$77.0 million, down 25.51%.
  • Equity Average for Q4 2025 was -$99.1 million at Foghorn Therapeutics, down from -$83.2 million in the prior quarter.
  • Over the last five years, Equity Average for FHTX hit a ceiling of $135.7 million in Q1 2021 and a floor of -$99.1 million in Q4 2025.
  • Median Equity Average over the past 5 years was -$29.1 million (2024), compared with a mean of -$2.6 million.
  • Biggest five-year swings in Equity Average: surged 1282.56% in 2021 and later tumbled 650.76% in 2023.
  • Foghorn Therapeutics' Equity Average stood at $88.9 million in 2021, then tumbled by 86.26% to $12.2 million in 2022, then tumbled by 650.76% to -$67.3 million in 2023, then skyrocketed by 45.15% to -$36.9 million in 2024, then tumbled by 168.45% to -$99.1 million in 2025.
  • The last three reported values for Equity Average were -$99.1 million (Q4 2025), -$83.2 million (Q3 2025), and -$69.2 million (Q2 2025) per Business Quant data.